Silas Inman

Final results from the phase II PALOMA-1 trial continue to support the dramatic efficacy of palbociclib plus letrozole in postmenopausal patients with locally advanced or newly diagnosed estrogen receptor ER-positive, HER2-negative metastatic breast cancer.

The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.

The BRAF inhibitor dabrafenib (Tafinlar) has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.

The FDA has granted an accelerated approval to the combination of the MEK inhibitor trametinib and the BRAF inhibitor dabrafenib as a treatment for patients with unresectable or metastatic melanoma that harbors a BRAF V600E or V600K mutation.

The mTOR inhibitor temsirolimus has limited utility in combination with frontline bevacizumab and as a second-line single agent for patients with metastatic renal cell carcinoma

Alterations in specific genes involved in the formation of tissues and organs during embryonic development could be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer.

To gain insight into the studies being presented at the ASH Annual Meeting, we interviewed Marcel R.M. van den Brink, MD, PhD, on abstracts being presented by faculty at Memorial Sloan-Kettering Cancer Center.

Ramucirumab, a monoclonal antibody that targets VEGFR-2, significantly prolonged survival in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following progression on first-line therapy, according to results from the phase III REGARD study published in The Lancet.

Marcia Brose, MD, sat down with OncLive at the Chemotherapy Foundation Symposium in New York City to discuss recent advances in the treatment of thyroid cancer.

The FDA has expanded the approval for sorafenib to include the treatment of patients with RAI-resistant metastatic differentiated thyroid cancer, based a substantial prolongation in PFS over placebo in the DECISION trial.

Eribulin has demonstrated a high level of antitumor activity that was equivalent or superior to vincristine across several sarcoma xenograft models, including at low dose levels, suggesting the drug may effectively treat pediatric patients with sarcoma.

The investigational autologous dendritic cell vaccine AGS-003 successfully activated a cytotoxic T cell response that correlates with a prolongation in survival for patients with metastatic renal cell carcinoma

Acting ahead of schedule, the FDA has granted an accelerated approval to ibrutinib as a treatment for patients with mantle cell lymphoma who have received at least one prior therapy.

The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.

Marketing and commercial distribution of ponatinib has been temporarily suspended, following an ongoing FDA investigation that revealed an increased frequency of arterial thrombosis and severe narrowing of the blood vessels.

The PD-1 blocking antibody nivolumab continues to demonstrate sustained clinical activity in previously treated patients with advanced non-small cell lung cancer.

The FDA has assigned a priority review designation to ramucirumab as a second-line treatment for patients with advanced gastric cancer.

The phase III EPIC trial that was exploring ponatinib in untreated patients with chronic myeloid leukemia has been discontinued following a high occurrence of arterial thrombotic events.

A VEGF level greater than 0.5 ng/mL in bile aspirated from the pancreas was 93% effective at identifying pancreatic cancer in patients with biliary stricture

A phase III study of the PI3K-delta inhibitor idelalisib in combination with rituximab has been stopped early following a positive interim analysis.

The FDA has placed a partial hold on the clinical development of the BCR-ABL inhibitor ponatinib, following the high occurrence of arterial thrombosis in patients treated with the drug.

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) have released updated recommendations for HER2 testing in breast cancer.

The investigational immunotherapy MK-3475 has demonstrated an objective response rate of up to 24% in patients with previously treated non-small cell lung cancer

Pertuzumab in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer

The novel PLK1 inhibitor volasertib in combination with low-dose cytarabine has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with untreated AML.

The FDA has approved the first generic formulation of capecitabine, an oral chemotherapeutic that is currently approved to treat patients with metastatic colorectal cancer and metastatic breast cancer.

A phase III trial examining the anti-CTLA-4 immune checkpoint inhibitor ipilimumab in men with metastatic castration-resistant prostate cancer failed to meet its primary endpoint of prolongation in overall survival.

The novel HDAC inhibitor entinostat in combination with exemestane has received a Breakthrough Therapy designation from the FDA for its potential to reverse resistance to hormonal therapies used to treat patients with advanced ER-positive breast cancer.

The FDA has approved nab-paclitaxel plus gemcitabine as a first-line treatment for patients with metastatic adenocarcinoma of the pancreas, an area of high unmet need with few effective treatments.